JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic ...
Prior to initiating JATENZO, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these testosterone concentrations are below the normal range. Individualize the dosage of JATENZO based on the patient's serum testosterone concentration response to the drug. The recommended starting dose is 237 mg taken oral...
JATENZO (testosterone undecanoate) capsules are available in three strengths of 158 mg, 198 mg, and 237 mg. Capsules are packaged as 120 units in wide-mouth, round, white HDPE bottles with white, polypropylene, child resistant caps and induction-sealed liner. 158 mg capsules are opaque red capsules imprinted with “158” in white ink and are supplied in bottles: NDC 69087-158-12. 198 mg capsules are opaque white cap...
www.fda.gov/medwatch
www.JATENZO.comBoxed Warning, Increases in Blood Pressure Removed 03/2025
Indications and Usage (1) 03/2025
Contraindications, Men with “age related hypogonadism” (4) Removed 03/2025
Warnings and Precautions , Venous Thromboembolism (5.2) 03/2025
Warnings and Precautions, Blood Pressure Increases (5.4) 03/2025
Warnings and Precautions, Cardiovascular Risk (5.3) Removed 03/2025
JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:
Limitations of use:
Prior to initiating JATENZO, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these testosterone concentrations are below the normal range.
Individualize the dosage of JATENZO based on the patient's serum testosterone concentration response to the drug. The recommended starting dose is 237 mg taken orally twice daily, once in the morning and once in the evening. Take JATENZO with food.
Dose Adjustment
To ensure proper dose adjustment, measure serum testosterone concentrations 6 hours after the morning dose in plain tubes, clotted at room temperature for 30 minutes prior to centrifugation. Adjust the JATENZO dose based on this serum testosterone measurement as shown in Table 1. Wait seven days after starting treatment or adjusting the dose before checking the serum testosterone concentration. Thereafter, periodically monitor serum testosterone concentrations 6 hours after the morning dose.
Administer the same dose in the morning and evening. The minimum recommended dose is 158 mg twice daily. The maximum recommended dose is 396 mg (two 198 mg capsules) twice daily.
| Testosterone Concentration in Serum From Plain Tube Drawn 6 hours After Morning Dose | Current JATENZO Dose (mg, twice daily) | New JATENZO Dose (mg, twice daily) |
| Less than 425 ng/dL | 158 | 198 |
| 198 | 237 | |
| 237 | 316 (two 158 mg capsules) | |
| 316 (two 158 mg capsules) | 396 (two 198 mg capsules) | |
| 425 ng/dL – 970 ng/dL | No Dose Change | |
| More than 970 ng/dL | 396 (two 198 mg capsules) | 316 (two 158 mg capsules) |
| 316 (two 158 mg capsules) | 237 | |
| 237 | 198 | |
| 198 | 158 | |
| 158 | Discontinue Treatment | |
JATENZO capsules for oral use are available in three strengths:
JATENZO is contraindicated in:
Increases in hematocrit reflective of increases in red blood cell mass, may require lowering the dose or discontinuation of JATENZO. Check that hematocrit is not elevated prior to initiating JATENZO. Evaluate hematocrit approximately every 3 months while the patient is on JATENZO. If hematocrit becomes elevated, stop JATENZO until the hematocrit decreases to an acceptable concentration. If JATENZO is restarted and again causes hematocrit to become elevated, stop JATENZO permanently. An increase in red blood cell mass may increase the risk of thromboembolic events [see Warnings and Precautions (5.2)].
There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone replacement products such as JATENZO.
In the Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study, a randomized, double-blind, placebo-controlled, cardiovascular (CV) outcomes study, compared to placebo, topical testosterone gel was associated with a numerically higher incidence of VTE (1.7% vs 1.2%) which included DVT (0.6% vs 0.5%) and PE events (0.9% vs 0.5%) [see Adverse Reactions (6.1)].
Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with JATENZO and initiate appropriate workup and management [see Adverse Reactions (6.2)].
Patients with BPH treated with androgens are at an increased risk for worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms.
Patients treated with androgens may be at increased risk for prostate cancer. Evaluate patients for prostate cancer prior to initiating and during treatment with androgens [see Contraindications (4)].
JATENZO can increase blood pressure. Ambulatory blood pressure monitoring (ABPM) demonstrated JATENZO increased systolic /diastolic BP by an average of 4.9/2.5 mm Hg from baseline after 4 months of treatment in a clinical trial [see Adverse Reactions (6.1)]. In patients with hypertension on antihypertensive therapy, JATENZO increased the mean systolic/diastolic BP by 5.4/3.2 mm Hg from baseline. Average blood pressures had not plateaued at the end of the trial.
The CV risk associated with topical testosterone gel was evaluated in TRAVERSE, a randomized, double-blind, placebo-controlled, CV outcomes study in men with a history of CV disease or multiple CV risk factors. In TRAVERSE, topical testosterone gel increased mean systolic blood pressure by 1.0 mm Hg from baseline to 36 months, whereas a mean decrease from baseline of 0.5 mm Hg was observed in the placebo group at this timepoint, for a mean between-group difference of 1.5 mm Hg. However, the incidences of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction [MI] and non-fatal stroke, were similar between treatment groups (7% for topical testosterone gel vs 7.3% for placebo) [See Adverse Reactions (6.1)].
Monitor blood pressure periodically in men using JATENZO, especially men with hypertension. JATENZO is not recommended for use in patients with uncontrolled hypertension.
Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions [see Drug Abuse and Dependence (9)].
If testosterone abuse is suspected, check testosterone concentrations to ensure they are within therapeutic range [see Dosage and Administration (2)]. However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.
With large doses of exogenous androgens, including JATENZO, spermatogenesis may be suppressed through feedback inhibition of pituitary FSH possibly leading to adverse effects on semen parameters including sperm count [see Use in Specific Populations (8.3)]. Patients should be informed of this possible risk when deciding whether to use or to continue to use JATENZO.
Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas. JATENZO is not known to cause these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g. jaundice). If these occur, promptly discontinue JATENZO while the cause is evaluated.
Androgens, including JATENZO, may promote retention of sodium and water. Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.
Gynecomastia may develop and persist in patients being treated for hypogonadism.
The treatment of hypogonadal men with testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.
Changes in the serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.
Androgens, including JATENZO, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Monitor serum calcium concentrations regularly during treatment with JATENZO in these patients.
Androgens, including JATENZO, may decrease concentrations of thyroxin-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
Depression and suicidal ideation has been reported in patients treated with JATENZO in clinical trials. Advise patients and caregivers to seek medical attention for manifestations of new onset or worsening depression, suicidal ideation or behavior, anxiety, or other mood changes [see Adverse Events (6.1)].
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of JATENZO was evaluated in a randomized, controlled clinical study with 166 patients treated with JATENZO twice daily with morning and evening meals for approximately 4 months. All patients were started on 237 mg twice daily, then the dose was titrated to 158 mg, 198 mg, 316 mg, or 396 mg twice daily to achieve testosterone concentrations in the eugonadal range.
Table 2 summarizes adverse reactions (≥2%) reported in this 4-month study.
Among the 569 patients who received JATENZO in all Phase 2 and 3 trials combined, the following adverse reactions were reported in >2% of patients: polycythemia, diarrhea, dyspepsia, eructation, peripheral edema, nausea, increased hematocrit, headache, prostatomegaly, and hypertension. | |
Three of the 166 patients (1.8%) in the 4-month study experienced adverse reactions that led to premature discontinuation from the study, including rash (n=1) and headache (n=2). | |
| Preferred Term | Overall (N = 166) n (%) |
| Headache | 8 (4.8) |
| Hematocrit increased | 8 (4.8) |
| Hypertension | 6 (3.6) |
| High-density lipoprotein decreased | 5 (3.0) |
| Nausea | 4 (2.4) |
BP Increases
In the 4-month clinical study, 24-hour ABPM was conducted on 166 patients. ABPM was conducted at baseline and at Day 139 of JATENZO therapy. A total of 135 patients had acceptable ABPM recordings at both time periods and were at least 85% compliant with study drug. In that group, the mean change in 24-hour systolic BP and diastolic BP from baseline to final on-treatment visit on Day 139 (n=135) was +4.9 mm Hg (95% CI 3.5, 6.4) and +2.5 mm Hg (95% CI 1.5, 3.6), respectively.
In patients with a history of hypertension who were receiving antihypertensive therapy, the mean ABPM systolic and diastolic BP increased by 5.4 mm Hg [95% CI 3.3, 7.6] and 3.2 mm Hg [95% CI 1.7, 4.7], respectively [n=67]. In patients with no history of hypertension, the mean ABPM systolic and diastolic blood pressure increased by 4.4 mm Hg [95% CI 2.3, 6.4] and 1.8 mm Hg [95% CI 0.2, 3.3], respectively [n=63].
Twelve (7.2%) patients on JATENZO either started antihypertensive medications or had their antihypertensive regimen increased during the study.
A total of 6 patients were reported to have an adverse reaction of hypertension (2 patients with hypertension and 4 patients with worsening hypertension), and 3 were reported to have an adverse reaction of increased blood pressure.
HR Increases
JATENZO increased mean heart rate by an average of 2.2 beats per minute (bpm) [95% CI (1.0, 3.3), N=135] during the study. Patients without a history of hypertension had a greater average increase in mean heart rate (2.7 bpm [95% CI (0.8, 4.6), N=63]) compared to patients with treated hypertension (1.9 bpm [95% CI (0.3, 3.5), N=67)]).
Increases in Hematocrit
Increases in hematocrit were reported in 8 of the 166 (4.8%) patients, which occurred in the second half of the study. None of these increases led to premature discontinuation of JATENZO.
Headaches
Headaches were reported in 8 of the 166 patients (4.8%) of which three required treatment with analgesics or non-steroidal anti-inflammatory drugs and 2 led to premature discontinuation from the study. Five of these 8 patients had headache events that resolved within 1 to 2 days.
Depression and suicidal ideation
Two of the 166 patients (1.2%) reported either worsening depression (n=1) or new-onset depression (n=1). One of the 569 patients (0.2%) in clinical trials had suicidal ideation. Each patient completed the study.
Increases in Serum PSA
The mean increase from baseline in PSA was 0.2 ng/mL (n=161). Increases in serum PSA concentrations, defined as an increase from baseline of at least 1.4 ng/mL or PSA greater than 4 ng/mL, occurred in 3 (1.9%) of the patients at the final visit.
Cardiovascular Outcomes
TRAVERSE was a randomized, double-blind, cardiovascular outcomes study to assess the cardiovascular (CV) safety of topical testosterone gel compared to placebo in 5198 hypogonadal men aged 45 to 80 years with a history of CV disease or with multiple CV risk factors. The primary outcome was the incidence of the composite endpoint of major adverse cardiovascular events (MACE), consisting of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.
The mean duration of therapy was approximately 22 months. The mean duration of follow-up was 33 months. Approximately 61% of all patients discontinued topical testosterone gel or placebo therapy.
The mean patient age (±SD) was 63.3 (7.9) years, with 2452 patients aged 65 years or more (47%); 2847 (about 55%) patients had pre-existing cardiovascular disease, whereas 2357 patients (about 45%) had an elevated cardiovascular risk at baseline, and mean BMI was 35kg/m2. Approximately 80% of patients were White, 17% were Black, and 3% were of other races or ethnic groups. Approximately 69%, 84%, and 93% had diabetes mellitus, hyperlipidemia, and hypertension, respectively.
The mean serum testosterone concentration at baseline in patients receiving topical testosterone gel was 220.4 ng/dL (n=2596). The mean serum testosterone concentrations at 12 months, 24 months, 36 months, and 48 months in patients receiving topical testosterone gel were 440.5 ng/dL (n=1683), 420.9 ng/dl (n=1125), 428.7 ng/dL (n=731), and 365.2 ng/dL (n=220), respectively.
For patients treated with topical testosterone gel, the incidence of MACE was 7.0% (n=182 events) and for those receiving placebo, the incidence of MACE was 7.3% (n=190 events). The study demonstrated non-inferiority of topical testosterone gel versus placebo because the upper bound of 95% CI was less than the pre-specified risk margin, of 1.5 for MACE (Hazard Ratio 0.96 [95% CI: 0.78, 1.17]).
Additional Adverse Reactions Reported in TRAVERSE
Additional adverse reactions reported in TRAVERSE at an incidence rate >2% in either treatment group and greater in topical testosterone gel versus placebo included: nonfatal arrythmias warranting intervention (5.2% vs 3.3%), atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and bone fracture (3.5% vs 2.5%). For the adverse reaction of bone fracture, each event was adjudicated by clinical review.
The following adverse reactions have been identified during post-approval use of testosterone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiovascular Disorders: myocardial infarction, stroke [see Warnings and Precautions (5.4), Clinical Trial Experience (6.1)]
Vascular Disorders: Venous thromboembolism [see Warnings and Precautions (5.1)]
Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of anti-diabetic medication.
Changes in anticoagulant activity may be seen with androgens; therefore, more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy.
The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring particularly in patients with cardiac, renal or hepatic disease.
Some prescription medications and nonprescription analgesic and cold medications contain drugs known to increase blood pressure. Concomitant administration of these medications with JATENZO may lead to additional increases in blood pressure [see Warnings and Precautions (5.4)].
Risk Summary
JATENZO is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm based on data from animal studies and its mechanism of action [see Contraindications (4) and Clinical Pharmacology (12.1)]. Exposure of a female fetus to androgens may result in varying degrees of virilization. In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring. These studies did not meet current standards for nonclinical development toxicity studies.
Data
Animal Data
In developmental studies conducted in rats, rabbits, pigs, sheep and rhesus monkeys, pregnant animals received intramuscular injection of testosterone during the period of organogenesis. Testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female and male offspring. Structural impairments observed in females included increased anogenital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. Structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen. Increased pituitary weight was seen in both sexes.
Testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. Hypertension was observed in pregnant female rats and their offspring exposed to doses approximately twice those used for testosterone replacement therapy.
Risk Summary
JATENZO is not indicated for use in women.
Infertility
During treatment with large doses of exogenous androgens, including JATENZO, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis [see Warnings and Precautions (5.7)], possibly leading to adverse effects on semen parameters including sperm count. Reduced fertility is observed in some men taking testosterone replacement therapy. Testicular atrophy, subfertility, and infertility have also been reported in men who abuse anabolic androgenic steroids [see Drug Abuse and Dependence (9.2)]. With either type of use, the impact on fertility may be irreversible.
The safety and efficacy of JATENZO in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.
There have not been sufficient numbers of geriatric patients involved in controlled clinical studies utilizing JATENZO to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. No patients over 65 years of age were enrolled in the 4-month efficacy and safety clinical study utilizing JATENZO. Additionally, there is insufficient long-term safety data in geriatric patients utilizing JATENZO to assess the potentially increased risk of cardiovascular disease and prostate cancer.
Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of BPH [see Warnings and Precautions (5.3)].
JATENZO contains testosterone undecanoate, which is a Schedule III controlled substance as defined under the Controlled Substances Act.
Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice.
Abuse-Related Adverse Reactions
Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression.
The following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility.
The following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities.
The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty.
Because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Behaviors Associated with Addiction
Continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors:
Physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. Individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism.
Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented.
There is a single report of acute overdosage with use of an approved injectable testosterone product: this subject had serum testosterone concentrations of up to 11,400 ng/dL which were implicated in a cerebrovascular accident.
One case of overdose with JATENZO was reported in clinical trials. This patient inadvertently took a higher dose than prescribed (474 mg twice daily, which is 20% higher than the maximum recommended dose). He did not report any adverse reactions associated with the overdose.
Treatment of overdosage consists of discontinuation of JATENZO and appropriate symptomatic and supportive care.
JATENZO (testosterone undecanoate) for oral use is provided as a gelatin capsule containing testosterone undecanoate, a fatty-acid ester of testosterone. Testosterone undecanoate is a white to off-white yellow crystalline powder. Testosterone, an androgen, is formed by cleavage of the ester side chain of testosterone undecanoate.
Testosterone undecanoate is chemically described as 17β-hydroxyandrost-4-en-3-one undecanoate. It has the empirical formula of C30H48O3 and the molecular weight of 456.7. The structural formula for testosterone undecanoate is presented in Figure 1.
Figure 1: Testosterone Undecanoate
JATENZO capsules are available in three strengths of 158 mg, 198 mg, and 237 mg.
The 158 mg strength is an opaque red capsule that contains 158 mg of testosterone undecanoate and is imprinted with “158” in white ink. The 198 mg strength is an opaque white capsule that contains 198 mg of testosterone undecanoate and is imprinted with “198” in red ink. The 237 mg strength is an opaque orange capsule that contains 237 mg of testosterone undecanoate and is imprinted with “237” in white ink. All capsule strengths also contain oleic acid, polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), borage seed oil, peppermint oil, and butylated hydroxytoluene as inactive ingredients.
Gelatin capsule shells are composed of the following inactive ingredients: Gelatin, sorbitol, glycerin, and purified water in all strengths, iron oxide red in 158 mg, FD&C Yellow #6 in 158 and 237 mg, and titanium dioxide in 198 and 237 mg capsules.
Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature and fat distribution.
Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter syndrome or Leydig cell aplasia, whereas secondary hypogonadism (also known as hypogonadotropic hypogonadism) is the failure of the hypothalamus (or pituitary) to produce sufficient gonadotropins (FSH, LH).
No specific pharmacodynamic studies were conducted using JATENZO.
Absorption
JATENZO delivers physiologic amounts of testosterone, producing testosterone concentrations that approximate normal concentrations seen in healthy men.
JATENZO was taken orally at a starting dose of 237 mg twice per day with meals in a multicenter, open-label, randomized, 2-arm, active-controlled trial in hypogonadal males. The dose was adjusted, as needed, on Days 14 and 56 between a minimum of 158 mg twice per day and a maximum of 396 mg twice per day based on the average plasma testosterone concentration obtained over 24 hours after the morning dose. The average daily NaF-EDTA plasma testosterone concentration was 403 (± 128) ng/dL at the end of treatment, where the normal eugonadal range in NaF-EDTA plasma was 252-907 ng/dL in this study. Note that the titration scheme for use in clinical practice is based on serum total testosterone [see Dosage and Administration (2.2)].
Table 3 summarizes the pharmacokinetic (PK) parameters for plasma total testosterone in patients completing at least 105 days of JATENZO treatment administered twice daily.
PK = pharmacokinetic; Cavg = 24-hour average concentration; Cmax = maximum concentration | ||
| PK Parameter | All Doses (N=151) | |
| Cavg (ng/dL) | Mean | 403 |
| SD | 128 | |
| Cmax (ng/dL) | Mean | 1008 |
| SD | 581 | |
Figure 2 summarizes the mean plasma total testosterone profile for the patients at the final PK visit.
Figure 2: Mean (±SEM) Concentration-Time Profile for NaF-EDTA Plasma Total Testosterone in JATENZO Treated Subjects at Final PK Visit  SEM = standard error of the mean; T = testosterone |
When JATENZO was dosed with different breakfasts containing various amounts of fat, the bioavailability with the 30 g fat, 45 g fat, and high-calorie high-fat breakfasts was comparable, but there was a food effect with the 15 g fat breakfast compared to the 30 g fat breakfast. The 15 g fat breakfast had a 25% decrease in testosterone exposure compared to the 30 g fat breakfast.
Distribution
Circulating testosterone is primarily bound in serum to sex hormone-binding globulin (SHBG) and albumin. Approximately 40% of testosterone in plasma is bound to SHBG, 2% remains unbound (free) and the rest is loosely bound to albumin and other proteins.
Metabolism
The androgenic activity of testosterone undecanoate occurs after the ester bond linking the testosterone to the undecanoic acid is cleaved by endogenous non-specific esterases. Undecanoic acid is metabolized like all fatty acids via the beta-oxidation pathway.
Testosterone is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of testosterone are dihydrotestosterone (DHT) and estradiol.
Drug Interaction Studies
Clinical Pharmacology Studies
Concomitant administration of JATENZO at 237 mg dose with midazolam (CYP3A4 substrate), digoxin (P-gp substrate), and rosuvastatin (BCRP substrate) had no clinically meaningful effect on the concentration of these substrates.
The potential for JATENZO doses higher than 237 mg to inhibit CYP3A4, P-gp and BCRP is unknown.
Excretion
About 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites. About 6% of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver.
Carcinogenesis
Testosterone has been tested by subcutaneous injection and implantation in mice and rats. In mice, the implant induced cervical-uterine tumors, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.
Mutagenesis
Testosterone was negative in the in vitro Ames and in the in vivo mouse micronucleus assays.
Impairment of Fertility
The administration of exogenous testosterone suppresses spermatogenesis in the rat, dog and non-human primates, which was reversible on cessation of the treatment.
JATENZO has been evaluated in 3- and 9-month repeat-dose oral toxicity studies in male eugonadal dogs. JATENZO caused exaggerated pharmacological effects on androgen-responsive tissues including testes, epididymis, prostate and adrenals at exposures to testosterone or testosterone undecanoate, comparable to the maximum human exposure based on AUC comparisons. Following a 4-week drug-free period, a reduced severity of these findings was observed, suggesting partial reversibility.
In adrenal glands, moderate to severe atrophy, characterized as thinning of the zona fasciculata, was observed with reduced adrenal weights and reduced circulating levels of cortisol in testosterone undecanoate-treated dogs after 3 months of treatment. Following 9-month treatment, there were dose-related decreases in adrenal weights in testosterone undecanoate-treated male dogs and moderate adrenal vacuolation in one testosterone undecanoate-treated male dog. The clinical significance of these adrenal and cortisol findings is unknown.
The efficacy and safety of JATENZO was evaluated in 166 adult hypogonadal males in an open-label study of approximately 4 months duration (NCT02722278). The study included a Screening Phase, a Treatment Titration Phase, and a Treatment Maintenance Phase.
JATENZO was taken orally at a starting dose of 237 mg twice per day with meals. The dose was adjusted on Days 21 and 56 between a minimum of 158 mg twice per day and a maximum of 396 mg twice per day on the basis of the average testosterone concentration obtained over 24 hours post-morning dose.
The primary endpoint was the percentage of patients with mean plasma total testosterone concentration (Cavg) over 24-hours within the normal eugonadal range on the final PK visit of the study.
Secondary endpoints were the percentage of patients with a maximum total testosterone concentration (Cmax) above three predetermined limits: less than or equal to 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL.
One hundred and forty-five (87%) of the 166 hypogonadal men who received JATENZO had a mean total testosterone concentration (Cavg) within the normal eugonadal range at the end of treatment.
The percentage of patients who received JATENZO and had Cmax less than or equal to 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL at the final PK visit were 83%, 3%, and 3%, respectively. Note that the testosterone concentrations were not measured in serum but the effects of different sample preparation conditions were accounted for in data analysis of the results shown here. The titration scheme for use in clinical practice is based on serum total testosterone [see Dosage and Administration (2.2)].
JATENZO (testosterone undecanoate) capsules are available in three strengths of 158 mg, 198 mg, and 237 mg. Capsules are packaged as 120 units in wide-mouth, round, white HDPE bottles with white, polypropylene, child resistant caps and induction-sealed liner.
158 mg capsules are opaque red capsules imprinted with “158” in white ink and are supplied in bottles: NDC 69087-158-12.
198 mg capsules are opaque white capsules imprinted with “198” in red ink and are supplied in bottles: NDC 69087-198-12.
237 mg capsules are opaque orange capsules imprinted with “237” in white ink and are supplied in bottles: NDC 69087-237-12.
Keep JATENZO out of reach of children.
Store at 20°C to 25ºC (68°F to 77ºF), excursions permitted to 15ºC to 30ºC (59ºF to 86ºF). Avoid exposing the capsules to moisture (store in a dry place).
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Venous Thromboembolism
Increased Blood Pressure
Other Adverse Reactions
Inform patients that treatment with androgens may lead to adverse reactions which include:
Instruct patients to report any changes in their state of health, such as changes in urinary habits, breathing, sleep, and mood including new onset or worsening of depression, or suicidal ideation.
Keep JATENZO out of the reach of children.
Distributed by:
Tolmar, Inc. Fort Collins, CO 80526
133462 Rev. 1 09/2025
This Medication Guide has been approved by the U.S. Food and Drug Administration | Issued: 09/2025 | |
| MEDICATION GUIDE JATENZO® (juh-TEN-zoh) (testosterone undecanoate) capsules, for oral use CIII | ||
What is JATENZO?
JATENZO is a controlled substance (CIII) because it contains testosterone that can be a target for people who abuse prescription medicines. Keep your JATENZO in a safe place to protect it. Never give your JATENZO to anyone else, even if they have the same symptoms you have. Selling or giving away this medicine may harm others and is against the law. | ||
Do not take JATENZO if you:
| ||
Before you take JATENZO, tell your healthcare provider about all of your medical conditions, including if you:
| ||
| Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using JATENZO with certain other medicines can affect each other. Especially, tell your healthcare provider if you take:
| ||
| Know the medicines you take. Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. | ||
How should I take JATENZO?
| ||
| What are the possible side effects of JATENZO? JATENZO may cause serious side effects including:
| ||
| Call your healthcare provider right away if you have any of the serious side effects listed above. The most common side effects of JATENZO include: | ||
|
|
|
| Other side effects include more erections than are normal for you or erections that last a long time.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of JATENZO. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||
How should I store JATENZO?
| ||
| Keep JATENZO and all medicines out of the reach of children. | ||
| General information about the safe and effective use of JATENZO Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use JATENZO for a condition for which it was not prescribed. Do not give JATENZO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about JATENZO that is written for health professionals. | ||
| What are the ingredients in JATENZO? Active ingredient: testosterone undecanoate Inactive ingredients: oleic acid, polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), borage seed oil, peppermint oil, and butylated hydroxytoluene. The ingredients of the soft gelatin capsule shells are gelatin, sorbitol, glycerin, purified water, iron oxide red, FD&C Yellow #6, and titanium dioxide. Distributed by: Tolmar, Inc. Fort Collins, CO 80526 For more information, go to www.JATENZO.com or call 1-844-4TO-LMAR.
| ||
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Data code | Data Matrix | 131923 | jatenzo-3.jpg | |
| Data code | Data Matrix | 131927 | jatenzo-5.jpg | |
| Data code | Data Matrix | 132755 | jatenzo-6.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 2db4fc38-a116-b0ab-3dae-57df54e5f212 | Product name | 2 | 20250121 |
| 386d1b2a-e9b7-0c83-111f-2a77b92895b3 | Product name | 5 | 20240422 |
| 7d55b53c-798b-47ae-992b-3921493a8303 | Product name | 1 | 20230322 |
| 8d753fd6-75b2-4f12-bcbf-339392960afa | Product name | 1 | 20230303 |
| 4fbda828-a5be-46fe-83ec-a88da4359919 | Product name | 1 | 20230104 |
| 93cc9bee-8bdc-273d-ec7f-c2c52535317a | Product name | 7 | 20210902 |
| a6389cd1-36d1-4b5c-9934-1139bee93605 | Product name | 5 | 20210601 |
| f4f0889f-ee8b-471f-9a37-02a035280637 | Product name | 1 | 20200122 |
| 09e1afd3-f431-4380-82c5-438884c25615 | Product name | 1 | 20190111 |
| a6389cd1-36d1-4b5c-9934-1139bee93605 | Product name | 3 | 20171212 |
| 502efed8-01a5-ef6a-61c6-fe8302b6e26b | Product name | 2 | 20171113 |
| 8b700cfd-17dd-41a2-90f5-a80ae8a989a2 | Product name | 1 | 20171113 |
| 9ce0e503-4ae7-2c6a-39ae-85285c29db68 | Product name | 2 | 20171113 |
| 96bdf4b3-71cd-433d-9723-89e50f852992 | Product name | 1 | 20150810 |
| ed2e617f-f28a-1df1-f9fc-c79702f31271 | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 69087-158-12 | EA - Each | 69087-158 | 94bde7a5-5f94-4c79-953f-24df127a348f | 1 | 2020-01-03 |
| 69087-198-12 | EA - Each | 69087-198 | 77ad506d-bb18-4207-bc32-85e159391822 | 1 | 2020-01-03 |
| 69087-237-12 | EA - Each | 69087-237 | 19f01d46-d70d-4333-98a2-351c91a6edb1 | 1 | 2020-01-03 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 69087-158 | 69087-158-12 |
| 69087-198 | 69087-198-12 |
| 69087-237 | 69087-237-12, 69087-237-28 |
Every source-derived ingredient row is available through these pages.
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 15 | 2026-10-06 | daily-update | 2026-10-10 01:06:23 |
| 13 | 2026-07-17 | daily-update | 2026-07-21 05:10:43 |
| 14 | 2025-09-30 | daily-update | 2026-07-25 05:10:44 |
| 12 | 2025-09-15 | full-release | 2026-05-31 21:43:03 |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N206089-001 | JATENZO | TESTOSTERONE UNDECANOATE | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | |
| N206089-002 | JATENZO | TESTOSTERONE UNDECANOATE | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | |
| N206089-003 | JATENZO | TESTOSTERONE UNDECANOATE | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N206089-001 | 11179402 | 2026-04-14 | Drug substance, Drug product | 2021-12-21 | |
| N206089-001 | 11331325 | 2027-01-06 | U-2506 | 2022-06-02 | |
| N206089-001 | 8241664 | 2029-03-29 | U-2506 | Drug product | 2019-04-08 |
| N206089-001 | 10543219 | 2030-04-12 | U-2506 | 2020-02-18 | |
| N206089-001 | 10617696 | 2030-04-12 | Drug substance, Drug product | 2020-05-05 | |
| N206089-001 | 11179403 | 2030-04-12 | U-2506 | 2021-12-21 | |
| N206089-001 | 11426416 | 2030-04-12 | U-3420 | 2022-09-12 | |
| N206089-001 | 8778916 | 2030-04-12 | Drug product | 2019-04-08 | |
| N206089-001 | 8492369 | 2030-12-20 | U-2506 | Drug product | 2019-04-08 |
| N206089-001 | 11564933 | 2039-04-12 | U-1103 | 2023-02-10 | |
| N206089-001 | 12605391 | 2039-04-12 | U-1103 | 2026-04-24 | |
| N206089-002 | 11179402 | 2026-04-14 | Drug substance, Drug product | 2021-12-21 | |
| N206089-002 | 11331325 | 2027-01-06 | U-2506 | 2022-06-02 | |
| N206089-002 | 8241664 | 2029-03-29 | U-2506 | Drug product | 2019-04-08 |
| N206089-002 | 10543219 | 2030-04-12 | U-2506 | 2020-02-18 | |
| N206089-002 | 10617696 | 2030-04-12 | Drug substance, Drug product | 2020-05-05 | |
| N206089-002 | 11179403 | 2030-04-12 | U-2506 | 2021-12-21 | |
| N206089-002 | 11426416 | 2030-04-12 | U-3420 | 2022-09-12 | |
| N206089-002 | 8778916 | 2030-04-12 | Drug product | 2019-04-08 | |
| N206089-002 | 8492369 | 2030-12-20 | U-2506 | Drug product | 2019-04-08 |
| N206089-002 | 11564933 | 2039-04-12 | U-1103 | 2023-02-10 | |
| N206089-002 | 12605391 | 2039-04-12 | U-1103 | 2026-04-24 | |
| N206089-003 | 11179402 | 2026-04-14 | Drug substance, Drug product | 2021-12-21 | |
| N206089-003 | 11331325 | 2027-01-06 | U-2506 | 2022-06-02 | |
| N206089-003 | 8241664 | 2029-03-29 | U-2506 | Drug product | 2019-04-08 |
| N206089-003 | 10543219 | 2030-04-12 | U-2506 | 2020-02-18 | |
| N206089-003 | 10617696 | 2030-04-12 | Drug substance, Drug product | 2020-05-05 | |
| N206089-003 | 11179403 | 2030-04-12 | U-2506 | 2021-12-21 | |
| N206089-003 | 11426416 | 2030-04-12 | U-3420 | 2022-09-12 | |
| N206089-003 | 8778916 | 2030-04-12 | Drug product | 2019-04-08 | |
| N206089-003 | 8492369 | 2030-12-20 | U-2506 | Drug product | 2019-04-08 |
| N206089-003 | 11564933 | 2039-04-12 | U-1103 | 2023-02-10 | |
| N206089-003 | 12605391 | 2039-04-12 | U-1103 | 2026-04-24 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N206089-002 | JATENZO | 198MG | CAPSULE / ORAL | RLD | 2019-03-27 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N206089-003 | JATENZO | 237MG | CAPSULE / ORAL | RLD, RS | 2019-03-27 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N206089-001 | JATENZO | 158MG | CAPSULE / ORAL | RLD | 2019-03-27 | 79d66fd596c7… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 11179402 | 2026-04-14 | Drug substance, Drug product | 2021-12-21 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 11331325 | 2027-01-06 | U-2506 | 2022-06-02 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 8241664 | 2029-03-29 | U-2506 | Drug product | 2019-04-08 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 10543219 | 2030-04-12 | U-2506 | 2020-02-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 10617696 | 2030-04-12 | Drug substance, Drug product | 2020-05-05 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 11179403 | 2030-04-12 | U-2506 | 2021-12-21 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 11426416 | 2030-04-12 | U-3420 | 2022-09-12 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 8778916 | 2030-04-12 | Drug product | 2019-04-08 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 8492369 | 2030-12-20 | U-2506 | Drug product | 2019-04-08 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 11564933 | 2039-04-12 | U-1103 | 2023-02-10 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-001 | 12605391 | 2039-04-12 | U-1103 | 2026-04-24 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 11179402 | 2026-04-14 | Drug substance, Drug product | 2021-12-21 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 11331325 | 2027-01-06 | U-2506 | 2022-06-02 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 8241664 | 2029-03-29 | U-2506 | Drug product | 2019-04-08 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 10543219 | 2030-04-12 | U-2506 | 2020-02-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 10617696 | 2030-04-12 | Drug substance, Drug product | 2020-05-05 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 11179403 | 2030-04-12 | U-2506 | 2021-12-21 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 11426416 | 2030-04-12 | U-3420 | 2022-09-12 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 8778916 | 2030-04-12 | Drug product | 2019-04-08 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 8492369 | 2030-12-20 | U-2506 | Drug product | 2019-04-08 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 11564933 | 2039-04-12 | U-1103 | 2023-02-10 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-002 | 12605391 | 2039-04-12 | U-1103 | 2026-04-24 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 11179402 | 2026-04-14 | Drug substance, Drug product | 2021-12-21 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 11331325 | 2027-01-06 | U-2506 | 2022-06-02 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 8241664 | 2029-03-29 | U-2506 | Drug product | 2019-04-08 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 10543219 | 2030-04-12 | U-2506 | 2020-02-18 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 10617696 | 2030-04-12 | Drug substance, Drug product | 2020-05-05 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 11179403 | 2030-04-12 | U-2506 | 2021-12-21 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 11426416 | 2030-04-12 | U-3420 | 2022-09-12 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 8778916 | 2030-04-12 | Drug product | 2019-04-08 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 8492369 | 2030-12-20 | U-2506 | Drug product | 2019-04-08 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 11564933 | 2039-04-12 | U-1103 | 2023-02-10 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N206089-003 | 12605391 | 2039-04-12 | U-1103 | 2026-04-24 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-001 | 11179402 | 2026-04-14 | Drug substance, Drug product | 2021-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-001 | 11331325 | 2027-01-06 | U-2506 | 2022-06-02 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-001 | 8241664 | 2029-03-29 | U-2506 | Drug product | 2019-04-08 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N206089-001 | 10543219 | 2030-04-12 | U-2506 | 2020-02-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-001 | 10617696 | 2030-04-12 | Drug substance, Drug product | 2020-05-05 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-001 | 11179403 | 2030-04-12 | U-2506 | 2021-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N206089-001 | 11426416 | 2030-04-12 | U-3420 | 2022-09-12 | 84e616aacf4f… |
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N206089-001 | NP | 2022-03-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N206089-002 | NP | 2022-03-27 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N206089-003 | NP | 2022-03-27 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N206089-001 | NP | 2022-03-27 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | N206089-002 | NP | 2022-03-27 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | N206089-003 | NP | 2022-03-27 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N206089-001 | NP | 2022-03-27 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | N206089-002 | NP | 2022-03-27 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | N206089-003 | NP | 2022-03-27 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N206089-001 | NP | 2022-03-27 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N206089-002 | NP | 2022-03-27 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N206089-003 | NP | 2022-03-27 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N206089-001 | NP | 2022-03-27 | bb7c543d1eb4… |
| 2022-03-09 01:35 UTC | 2022-03 | N206089-002 | NP | 2022-03-27 | bb7c543d1eb4… |
| 2022-03-09 01:35 UTC | 2022-03 | N206089-003 | NP | 2022-03-27 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N206089-001 | NP | 2022-03-27 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | N206089-002 | NP | 2022-03-27 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | N206089-003 | NP | 2022-03-27 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N206089-001 | NP | 2022-03-27 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N206089-002 | NP | 2022-03-27 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N206089-003 | NP | 2022-03-27 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N206089-001 | NP | 2022-03-27 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | N206089-002 | NP | 2022-03-27 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | N206089-003 | NP | 2022-03-27 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N206089-001 | NP | 2022-03-27 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | N206089-002 | NP | 2022-03-27 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | N206089-003 | NP | 2022-03-27 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N206089-001 | NP | 2022-03-27 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | N206089-002 | NP | 2022-03-27 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | N206089-003 | NP | 2022-03-27 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N206089-001 | NP | 2022-03-27 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N206089-002 | NP | 2022-03-27 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N206089-003 | NP | 2022-03-27 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N206089-001 | NP | 2022-03-27 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N206089-002 | NP | 2022-03-27 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N206089-003 | NP | 2022-03-27 | b00525d2431f… |
| 2023-01-26 05:58 UTC | 2023-01 | N206089-001 | NP | 2022-03-27 | 3bdfa0b2c4d7… |
| 2023-01-26 05:58 UTC | 2023-01 | N206089-002 | NP | 2022-03-27 | 3bdfa0b2c4d7… |
| 2023-01-26 05:58 UTC | 2023-01 | N206089-003 | NP | 2022-03-27 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N206089-001 | NP | 2022-03-27 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 9db3c914-8c33-4b65-86d3-5dc5c775b00b | ed7b5d41-7475-4c10-99b9-b62b3434ae60 | 2025-09-30 | Warnings, Adverse reactions | ed7b5d41-7475-4c10-99b9-b62b3434ae60 |
Adverse event summaries are temporarily unavailable. Other product information remains available.